SOCS5 mRNA levels in peripheral blood mononuclear cells (PBMC): A potential bio-marker for monitoring response of uveitis patients to Daclizumab therapy

Journal of Autoimmunity

Volumn 24, Issue 1, 2005, Pages 39-46

  Egwuagu, Charles E ^a,b   Yu, Cheng Rong ^a   Li, Zhuqing ^a   Nussenblatt, Robert B ^a  

^a NATIONAL EYE INSTITUTE   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

Bio marker; Daclizumab therapy; JAK STAT; SOCS; SOCS5; Uveitis

Indexed keywords

BIOLOGICAL MARKER; DACLIZUMAB; MESSENGER RNA; SUPPRESSOR OF CYTOKINE SIGNALING; SUPPRESSOR OF CYTOKINE SIGNALING 3; SUPPRESSOR OF CYTOKINE SIGNALING 5; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; ARTICLE; BIOLOGICAL MONITORING; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DATA ANALYSIS; DIAGNOSTIC VALUE; DISEASE MARKER; DRUG MONITORING; DRUG TARGETING; FEMALE; GENE; GENE EXPRESSION; HUMAN; INTERMETHOD COMPARISON; MALE; PATIENT COMPLIANCE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; STATISTICAL SIGNIFICANCE; SUPPRESSOR OF CYTOKINE SIGNALING 5 GENE; T LYMPHOCYTE ACTIVATION; UVEITIS;

EID: 13944258449     PISSN: 08968411     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaut.2004.11.006     Document Type: Article

References (23)

1. D.A. Jabs, J.T. Rosenbaum, C.S. Foster, G.N. Holland, G.J. Jaffe, and J.S. Louie Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel Am J Ophthalmol 130 2000 492 513
2. R.B. Nussenblatt, E. Fortin, R. Schiffman, L. Rizzo, J. Smith, and P. Van Veldhuisen Treatment of noninfectious intermediate and posterior uveitis with the humanized anti-Tac mAb: a phase I/II clinical trial Proc Natl Acad Sci U S A 96 1999 7462 7466
3. R.B. Nussenblatt Proctor lecture. Experimental autoimmune uveitis: mechanisms of disease and clinical therapeutic indications Invest Ophthalmol Vis Sci 32 1991 3131 3141
4. R.R. Caspi Th1 and Th2 responses in pathogenesis and regulation of experimental autoimmune uveoretinitis Int Rev Immunol 21 2002 197 208
5. R.B. Nussenblatt Bench to bedside: new approaches to the immunotherapy of uveitic disease Int Rev Immunol 21 2002 273 289
6. R.R. Caspi Regulation, counter-regulation, and immunotherapy of autoimmune responses to immunologically privileged retinal antigens Immunol Res 27 2003 149 160
7. F. Vincenti, R. Kirkman, S. Light, G. Bumgardner, M. Pescovitz, and P. Halloran Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation. Daclizumab Triple Therapy Study Group N Engl J Med 338 1998 161 165
8. R.B. Nussenblatt, D.J. Thompson, Z. Li, J.S. Peterson, R.R. Robinson, and R.S. Shames Humanized anti-interleukin-2 (IL-2) receptor alpha therapy: long-term results in uveitis patients and preliminary safety and activity data for establishing parameters for subcutaneous administration J Autoimmun 21 2003 283 293
9. C.E. Egwuagu, C.R. Yu, M. Zhang, R.M. Mahdi, S.J. Kim, and I. Gery Suppressors of cytokine signaling proteins are differentially expressed in Th1 and Th2 cells: implications for Th cell lineage commitment and maintenance J Immunol 168 2002 3181 3187
10. C.R. Yu, R.M. Mahdi, S. Ebong, B.P. Vistica, I. Gery, and C.E. Egwuagu Suppressor of cytokine signaling 3 regulates proliferation and activation of T-helper cells J Biol Chem 278 2003 29752 29759
11. Y. Seki, K. Hayashi, A. Matsumoto, N. Seki, J. Tsukada, and J. Ransom Expression of the suppressor of cytokine signaling-5 (SOCS5) negatively regulates IL-4-dependent STAT6 activation and Th2 differentiation Proc Natl Acad Sci U S A 99 2002 13003 13008
12. R.B. Nussenblatt, A.G. Palestine, C.C. Chan, and F. Roberge Standardization of vitreal inflammatory activity in intermediate and posterior uveitis Ophthalmology 92 1985 467 471
13. M.J. Hogan, S.J. Kimura, and P. Thygeson Signs and symptoms of uveitis. I. Anterior uveitis Am J Ophthalmol 47 1959 155 170
14. W. Li, C.N. Nagineni, H. Ge, B. Efiok, A.B. Chepelinsky, and C.E. Egwuagu Interferon consensus sequence-binding protein is constitutively expressed and differentially regulated in the ocular lens J Biol Chem 274 1999 9686 9691
15. W. Li, C.N. Nagineni, B. Efiok, A.B. Chepelinsky, and C.E. Egwuagu Interferon regulatory transcription factors are constitutively expressed and spatially regulated in the mouse lens Dev Biol 210 1999 44 55
16. A. Matsumoto, Y. Seki, R. Watanabe, K. Hayashi, J.A. Johnston, and Y. Harada A role of suppressor of cytokine signaling 3 (SOCS3/CIS3/SSI3) in CD28-mediated interleukin 2 production J Exp Med 197 2003 425 436
17. Y. Seki, H. Inoue, N. Nagata, K. Hayashi, S. Fukuyama, and K. Matsumoto SOCS-3 regulates onset and maintenance of T(H)2-mediated allergic responses Nat Med 9 2003 1047 1054
18. M.F. Neurath, S. Finotto, and L.H. Glimcher The role of Th1/Th2 polarization in mucosal immunity Nat Med 8 2002 567 573
19. T. Naka, M. Fujimoto, and T. Kishimoto Negative regulation of cytokine signaling: STAT-induced STAT inhibitor Trends Biochem Sci 24 1999 394 398
20. N.A. Nicola, S.E. Nicholson, D. Metcalf, J.G. Zhang, M. Baca, and A. Farley Negative regulation of cytokine signaling by the SOCS proteins Cold Spring Harb Symp Quant Biol 64 1999 397 404
21. D.L. Krebs, and D.J. Hilton SOCS proteins: negative regulators of cytokine signaling Stem Cells 19 2001 378 387
22. M. Narazaki, M. Fujimoto, T. Matsumoto, Y. Morita, H. Saito, and T. Kajita Three distinct domains of SSI-1/SOCS-1/JAB protein are required for its suppression of interleukin 6 signaling Proc Natl Acad Sci U S A 95 1998 13130 13134
23. H. Yasukawa, H. Misawa, H. Sakamoto, M. Masuhara, A. Sasaki, and T. Wakioka The JAK-binding protein JAB inhibits Janus tyrosine kinase activity through binding in the activation loop EMBO J 18 1999 1309 1320